GRPR and neoplasm: In the quest for radioligands with higher stability and potency, Nock et al. (2017) developed a novel GRPR antagonist NeoBOMB1, in which the C-terminal Leu13-Met14-NH2 dipeptide of SB3 to Sta13-Leu14-NH2 is replaced, displaying improved affinity for the GRPR and superior tumor localizing efficacy in rodent models and patients.